On January 21, Bohui Innovation (300318) recently released its 2021 annual performance forecast, and it is expected that the performance will turn from profit to loss year-on-year. During the reporting period, the net profit loss attributable to the shareholders of the listed company was 270 million yuan - 375 million yuan, which was from profit to loss compared with the same period of the previous year.
The company's net profit loss attributable to shareholders of the listed company during the reporting period was mainly due to:
Zhongke Biopharmaceutical Co., Ltd. (hereinafter referred to as "Zhongke Bio"), a subsidiary of the company, is maintaining and transforming production facilities in order to ensure the production of better and safer biological drugs, and is basically in a state of suspension in 2021, with a sharp decline in revenue and a large amount of downtime losses, which has a greater impact on the company's overall operating performance.
In order to consolidate the R&D foundation and support the construction of the Yunnan Blood System Project, the company increased its R&D investment and financing efforts, and the R&D and financial expenses increased year-on-year, affecting the company's operating performance.
Provision for impairment of goodwill. On the one hand, due to the suspension of production and transformation of Zhongke Biologics and the approval of the operation qualification of the pulp station under Zhongke Biologics, which was less than expected, there were signs of impairment in the goodwill formed by the acquisition of Zhongke Bio by Hebei Daan Pharmaceutical Co., Ltd., a holding subsidiary of the Company, and the Company conducted a preliminary impairment test and made corresponding impairment provisions. On the other hand, the company's holding subsidiary, Changzhou Pilot Quantum Biomedical Technology Co., Ltd. (hereinafter referred to as "Pilot Quantum"), due to the lower than expected operating performance, resulting in signs of impairment of the goodwill formed by the company's acquisition of Pilot Quantum, the company conducted a preliminary impairment test and made a corresponding impairment provision. According to preliminary calculations, the total amount of the above goodwill impairment provision is about 340 million yuan, affecting the net profit attributable to the shareholders of the listed company of about -240 million yuan.
According to the data of The Shell Network, Bohui Innovation is a biological high-tech enterprise integrating research and development, production, sales and after-sales service, and is committed to technological innovation. The company's business involves two subdivisions of inspection and testing and biological products. Inspection and testing business is mainly engaged in the research and development, production and sales of inspection instruments and testing reagents, of which the inspection and testing business operated by the parent company belongs to the pharmaceutical manufacturing industry of in vitro diagnostic products, and the Inspection and Testing business of the US subsidiary Advion is mainly for non-medical users. The biological products business is mainly engaged in the research and development, production and sales of blood products and vaccine products, and is operated by hebei daan pharmaceutical co., ltd. and Guangdong Weilun biopharmaceutical co., ltd., a holding subsidiary of the company.
This article originated from the digging shell network